FDA Approves Umbralisib for Marginal Zone Lymphoma, Follicular Lymphoma
Apr 15, 2021 ·
5m 25s
Sign up for free
Listen to this episode and many more. Enjoy the best podcasts on Spreaker!
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, discusses umbralisib, which was approved for the treatment of relapsed or refractory follicular lymphoma (FL) and relapsed or refractory marginal zone...
show more
Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, discusses umbralisib, which was approved for the treatment of relapsed or refractory follicular lymphoma (FL) and relapsed or refractory marginal zone lymphoma (MZL)
show less
Information
| Author | Peter Ciszewski, CheckRare |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
